Project: Developing Tools to assess Efficacy and Safety of the promising TEG treatment for solid tumors

Acronym TEST (Reference Number: 11497)
Duration 01/01/2018
Project Topic GAD’s new technology TEG to create T-cell immunotherapies(TCI) targets many cancers through its unique MoA, targeting tumor cells by recognizing surface markers of metabolic dysregulation. GAD, HUB&CT can image and quantify efficacy of TEGs and their ability to discriminate between healthy vs malignant tissue using organoids&RamanSpectroscopy. TEST aims to create PoC for TEG002 in Triple Negative Breast Cancer(TNBC) in organoids and mice (UoF) and to deliver a screening platform for novel TCIs.
Network Eurostars 2
Call Eurostars Cut-Off 7

Project partner

Number Name Role Country
1 Gadeta B.V. Coordinator Netherlands
2 CellTool Partner Germany
3 Hubrecht Organoid Technology Partner Netherlands
4 Albert-Ludwigs-Universität Freiburg Partner Germany